The impact of specialty pharmaceuticals as drivers of health care costs

Health Affairs

Volumn 33, Issue 10, 2014, Pages 1714-1720

  Hirsch, Bradford R ^a   Balu, Suresh ^b   Schulman, Kevin A ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BIOSIMILAR AGENT; BOSUTINIB; CABOZANTINIB; CARFILZOMIB; ENZALUTAMIDE; EVEROLIMUS; NEW DRUG; PAZOPANIB; PERTUZUMAB; PONATINIB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; REGORAFENIB; RITUXIMAB; TRASTUZUMAB; VISMODEGIB; BIOLOGICAL PRODUCT; PRESCRIPTION DRUG;

ARTICLE; CLINICAL PRACTICE; COMMUNITY CARE; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG INFUSION; DRUG MARKETING; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH INSURANCE; INJECTION; LAW; MEDICARE; MONITORING; MORALITY; OUTPATIENT CARE; PRESCRIPTION; REIMBURSEMENT; COST; DRUG LEGISLATION; ECONOMIC ASPECT; ECONOMICS; HUMAN; LEGISLATION AND JURISPRUDENCE; SAFETY NET HOSPITAL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; COST SHARING; DRUG COSTS; ECONOMIC COMPETITION; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; LEGISLATION, DRUG; PRESCRIPTION DRUGS; SAFETY-NET PROVIDERS; UNITED STATES;

EID: 84907807717     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.0558     Document Type: Article

References (38)

1. Spatz I, McGee N. Health Policy Brief: specialty pharmaceuticals. Health Affairs [serial on the Internet]. 2013 Nov 25 [cited 2014 Sep 2]. Available from: http://www.health affairs.org/healthpolicybriefs/ brief.php?brief_id=103
2. Schulman KA, Vidal AV, Ackerly DC. Personalized medicine and disruptive innovation: implications for technology assessment. Genet Med. 2009;11(8):577-81.
3. IMS use of medicines report: 2012 sales drop 1.0%-the first ever recorded decline. Pharmaceutical Commerce [serial on the Internet]. 2013 May 10 [cited 2014 Sep 2]. Available from: http://pharma ceuticalcommerce.com/latest_ news?articleid=26868
4. Schumock GT, Li EC, Suda KJ, Matusiak LM, Hunkler RJ, Vermeulen LC, et al. National trends in prescription drug expenditures and projections for 2014. Am J Health Syst Pharm. 2014;71(6): 482-99.
5. Express Scripts. 2011 drug trend report [Internet]. St. Louis (MO): Express Scripts; 2012 Apr [cited 2014 Sep 11]. Available from: http://lab.express-scripts.com/insights/ industry-updates/~/media/ b2d069aa4a2b4b188879a81ab0 bab8aa.ashx
6. Census Bureau. Statistical abstracts of the United States: 2012 [Internet]. Washington (DC): Census Bureau; 2012. Table 159: retail prescription drug sales: 1995 to 2010; [cited 2014 Sep 2]. Available from: http:// www.census.gov/compendia/ statab/2012/tables/12s0159.pdf
7. Langreth R. First million-dollar drug near after prices double on dozens of treatments. Bloomberg [serial on the Internet]. 2014 Apr 30 [cited 2014 Sep 2]. Available from: http:// www.bloomberg.com/news/2014-04-30/drug-prices-defy-gravitydoubling-for-dozens-of-products.html
8. Ramsey S, Fedorenko C, Snell K, Kirchhoff A, Hollingworth W, Blough D. Cancer diagnosis as a risk factor for personal bankruptcy. Paper presented at: American Society of Clinical Oncology Annual Meeting; 2011 Jun 3; Chicago, IL.
9. Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18(4): 381-90.
10. To access the Appendix, click on the Appendix link in the box to the right of the article online
11. Rasiel EB, Weinfurt KP, Schulman KA. Can prospect theory explain risk-seeking behavior by terminally ill patients? Med Decis Making. 2005;25(6):609-13.
12. Kahneman D. Thinking, fast and slow. New York (NY): Farrar, Strauss and Giroux; 2011.
13. Partnership for Prescription Assistance [Internet]. Washington (DC): The Partnership. Press release, Partnership for Prescription Assistance celebrates its eight anniversary; [cited 2014 Sep 11]. Available from: https://www.pparx.org/ news_and_media/press_releases/ 2013/partnership_for_ prescription_assistance: celebrates_its_eighth
14. Medicare.gov. Pharmaceutical Assistance Program [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [cited 2014 Sep 2]. Available from: http:// www.medicare.gov/pharmaceuticalassistance-program/
15. Congressional Budget Office. Change the cost-sharing rules for Medicare and restrict Medigap insurance [Internet]. Washington (DC): CBO; 2013 Nov 13 [cited 2014 Sep 2]. Available from: https:// www.cbo.gov/budget-options/ 2013/44895
16. Peters CP. The Medicaid Drug Rebate Program [Internet]. Washington (DC): The George Washington University National Health Policy Forum; 2009 Apr 13 [cited 2014 Sep 2]. Available from: http:// www.nhpf.org/library/the-basics/ basics_medicaiddrugrebate_04-13-09.pdf
17. Centers BJ. Apexus Inc. 340B pricing. Paper presented at: 340B University Conference; 2013 Mar 11; Baltimore, MD.
18. Government Accountability Office. Drug pricing: manufacturer discounts in the 340B program offer benefits, but federal oversight needs improvement [Internet]. Washington (DC): GAO; 2011 Sep [cited 2014 Sep 2]. Available from: http:// www.gao.gov/assets/330/ 323702.pdf
19. Conti RM, Bach PB. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities. Health Aff (Millwood). 2014;33(10): 1786-92.
20. Wright S. Memorandum report: payment for drugs under the hospital Outpatient Prospective Payment System [Internet].Washington (DC): Department of Health and Human Services Office of Inspector General; [cited 2014 Sep 2]. Available from: http://oig.hhs.gov/oei/reports/oei-03-09-00420.pdf
21. Pollack A. Dispute develops over drug discount program. New York Times. 2013 Feb 12.
22. Conti RM, Bach PB. Cost consequences of the 340B drug discount program. JAMA. 2013; 309(19):1995-6.
23. Moran Company. Results of an analysis for chemotherapy administration utilization and chemotherapy drug utilization, 2005-2011 for Medicare fee-for-service beneficiaries [Internet]. Arlington (VA): Moran Company; 2013 May 29 [cited 2014 Sep 2]. Available from: https:// media.gractions.com/E5820F8C11 F80915AE699A1BD4FA0948B 6285786/01655fe9-7f3d-4d9a-80d0-d2f9581673a1.pdf
24. Garloch K, Alexander A. Oncologists struggle to stay independent. Charlotte Observer. 2012 Sep 22.
25. Richman BD, Schulman KA. A cautious path forward on accountable care organizations. JAMA. 2011; 305(6):602-3.
26. IMS Institute for Healthcare Informatics. Innovation in cancer care and implications for health systems: global oncology trend report [Internet]. Plymouth Meeting (PA): The Institute; 2014 May [cited 2014 Sep 2]. Available from: http:// www.imshealth.com/cds/ imshealth/Global/Content/ Corporate/IMS%20Health%20 Institute/Reports/Secure/IMSH_ Oncology_Trend_Report.pdf
27. Office of Pharmacy Affairs. 340B Drug Pricing Program [Internet]. Washington (DC): Department of Health and Human Services; [cited 2014 Sep 11]. Available from: http:// hrsa.gov/opa/
28. American Society of Clinical Oncology. Policy statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology. J Oncol Pract. 2014;10(4):262.
29. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product [Internet]. Silver Spring (MD): FDA; 2012 Feb [cited 2014 Sep 2]. Available from: http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ UCM291134.pdf
30. FDA Center for Drug Evaluation and Research. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product [Internet]. Silver Spring (MD): FDA; 2012 Feb [cited 2014 Sep 2]. Available from: http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ UCM291128.pdf
31. FDA Center for Drug Evaluation and Research. Guidance for industry: formal meetings between FDA and biosimilar biological product sponsors or applicants [Internet]. Silver Spring (MD): FDA; 2013 Mar [cited 2014 Sep 2]. Available from: http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ UCM345649.pdf
32. Federal Trade Commission. Emerging health care issues: follow-on biologic drug competition [Internet]. Washington (DC): FTC; 2009 Jun [cited 2014 Sep 2]. Available from: http://www.ftc.gov/sites/default/ files/documents/reports/emerginghealth-care-issues-follow-biologicdrug-competition-federal-tradecommission-report/p083901 biologicsreport.pdf
33. Food and Drug Administration. Drugs: facts about generic drugs [Internet]. Silver Spring (MD): FDA; [last updated 2012 Sep 19; cited 2014 Sep 2]. Available from: http:// www.fda.gov/drugs/resourcesfor you/consumers/buyingusing medicinesafely/understanding genericdrugs/ucm167991.htm
34. Elmendorf DW. Letter to Paul Ryan [Internet]. Washington (DC): Congressional Budget Office; 2010 Nov 4 [cited 2014 Sep 2]. Available from: https://www.cbo.gov/sites/default/ files/cbofiles/ftpdocs/116xx/ doc11674/11-04-drug_pricing.pdf
35. Valverde AM, Reed SD, Schulman KA. Proposed "grant-and-access" program with price caps could stimulate development of drugs for very rare diseases. Health Aff (Millwood). 2012;31(11):2528-35.
36. Hirsch BR, Schulman KA. The economics of new drugs: can we afford to make progress in a common disease? Paper presented at: American Society of Clinical Oncology Annual Meeting; 2013 Jun 2; Chicago, IL.
37. Institute of Medicine. Envisioning a transformed clinical trials enterprise in the United States: establishing an agenda for 2020: workshop summary. Washington (DC): National Academies Press; 2012.
38. Coller BS, Califf RM. Traversing the valley of death: a guide to assessing prospects for translational success. Sci Transl Med. 2009;1(10):10cm9.